Is this your brand? Sign in to claim ownership.

Sign in to claim this brand

DIAGNOSTICA STAGO

France·FR-MF-000017089

Last updated May 23, 2026

What DIAGNOSTICA STAGO makes

Diagnostica Stago manufactures in vitro diagnostic (IVD) reagents and instruments for coagulation testing, including assays for immune deficiency markers (e.g., ImmunoDef II, ImmunoDef XII), von Willebrand factor (VWF:FVIIIB, VWF:CB), protein C, and epinephrine. Their portfolio also includes clotting reagents (e.g., Néoplastine® CI Plus 5, Collagen) and anticoagulant monitoring solutions (e.g., sthemO Anti-Xa M). The company produces both manual test kits (e.g., Asserachrom® series) and automated systems (e.g., STA Compact Max® 2) for laboratory use.

The company’s products are regulated under IVD General (Class A, B, C) and Class II classifications in the EU and FDA’s 510(k) pathway in the US. Devices are listed in the EU’s eudamed registry and the FDA’s 510(k) database. The manufacturer is based in France.

Written from this company's registered devices by an AI model, and not verified by a human reviewer.

Information

Country
France
Address
3, allée Thérésa, Asnières sur Seine, France
Website
stago.com
LinkedIn
—
Facebook
—
Phone
+33 (0)1 46 88 20 20
PRRC Contact
Sophie REHAULT
EUDAMED SRN
FR-MF-000017089
FDA FEI Number
—
DUNS Number
262277122

Catalogue (153)

Page 2 of 4
DeviceModel / ReferenceRegistriesClassStatus
STA® - CaCl2 0.01 M 00773
EUDAMED
Class AActive
STA® - Néoplastine® CI Plus 10 00667
EUDAMEDFDA UDI
Class CActive
STA Satellite Max® 58030
EUDAMED
Class AActive
STA® - Liquid Fib 00673
EUDAMED
Class BActive
Flacon de 1850 billes / 1850-Ball Vial 26441
EUDAMED
Class AActive
sthemO II 01229
EUDAMED
Class BActive
sthemO Fib M 01224
EUDAMED
Class BActive
Asserachrom® IX:Ag 00943
EUDAMEDFDA UDI
IVD GeneralActive
STA R Max® 59026
EUDAMEDFDA UDI
Class AActive
sthemO PTT A 01222
EUDAMED
Class CActive
STG® - ThrombiClean 01140
EUDAMED
Class AActive
STA Satellite Cuvettes 39430
EUDAMED
Class AActive
STA® - Quali-Clot I 00982
EUDAMED
Class CActive
sthemO Wash 01575
EUDAMED
Class AActive
STA R Max® 3 59028
EUDAMED
Class AActive
sthemO CK Prest 01223
EUDAMED
Class CActive
sthemO FDP cal 01246
EUDAMED
Class BActive
sthemA CAL-CBC 01400
EUDAMED
Class BActive
sthemO LA QC 1&2 01251
EUDAMED
Class BActive
sthemO CaCl2 M 01464
EUDAMED
Class AActive
sthemO FDP QC 1&2 01247
EUDAMED
Class BActive
Microcontainer 00741
EUDAMED
Class AActive
STA® - Cuvettes 38669
EUDAMED
Class AActive
STA Compact Max® 2 58990
EUDAMEDFDA UDI
Class AActive
STA® - Quality HBPM/LMWH 00686
EUDAMEDFDA UDI
Class CActive
Asserachrom® D-Di 00947
EUDAMEDFDA UDI
IVD GeneralActive
STA® - micro Reducer 00760
EUDAMED
Class AActive
Sta® - Eca Ii 00992
EUDAMED
Class CActive
Asserachrom® HPIA 00615
EUDAMEDFDA UDI
IVD GeneralActive
STA® - FM Calibrator 00544
EUDAMED
Class BActive
STA® - Liquid Anti-Xa 4 00311
EUDAMED
Class CActive
sthemO Unical 01254
EUDAMED
Class BActive
Asserachrom® Washing Solution 00555
EUDAMEDFDA UDI
Class AActive
sthemO dRVV confirm 01239
EUDAMED
Class BActive
sthemO Complete QC 1&2 01257
EUDAMED
Class CActive
STA® - D-Di Control 00868
EUDAMED
Class CActive
sthemO DDi M 01234
EUDAMED
Class CActive
STA® - Deficient IX 00724
EUDAMEDFDA UDI
Class BActive
STA® - Unicalibrator 00675
EUDAMEDFDA UDI
Class CActive
STA® - Owren-Koller 00360
EUDAMEDFDA UDI
Class AActive
Cuvettes 38876
EUDAMED
Class AActive
STA® - Hepato-Prest 10 00762
EUDAMED
Class CActive
Sta® - Spa + 00330
EUDAMED
Class CActive
STA® - Apixaban Control 01074
EUDAMED
Class CActive
sthemA CTR-L3 01403
EUDAMED
Class BActive
STA® - Staclot® Protein C 1 00747
EUDAMEDFDA UDI
Class BActive
sthemO Cuvettes 86931
EUDAMED
Class AActive
Asserachrom® Protein C 00944
EUDAMEDFDA UDI
IVD GeneralActive
STA® - Staclot® dRVV Screen 5 00333
EUDAMEDFDA UDI
Class BActive
sthemO DDi QC 1&2 01245
EUDAMED
Class CActive

Related Companies

Authorised Representatives

No authorised representatives on record.

Importers

Not available yet.

Notified Bodies

Not available yet.

Authorities

Not available yet.

FDA Recalls (41)

Recalls reported by this firm to the FDA. Listed at company level — FDA recall records don't identify a specific catalogue device.

Diagnostica Stago has initiated 41 recall records between December 4, 2002, and February 5, 2026, with statuses recorded as open, classified, or terminated. The reasons cited include assay inaccuracies (e.g., incorrect ranges, homogeneity defects, and clotting time discrepancies), measurement biases (e.g., positive or negative bias in D-Dimer, factor VIII/IX, and EQA results), potential contamination or cross-reactivity (e.g., sample contamination in Emicizumab assays or reagent cross-contamination), instrument failures (e.g., silicon bridge rectifier defects causing smoke and burnt components), and lot-specific performance issues (e.g., low results in Free Protein S assays or altered optical density measurements).

AI-generated summary of the recall records listed below. It describes what the records state and is not an assessment of this manufacturer.

DateRecall No.ClassStatusReason
Feb 5, 2026Z-1585-2026—open, classified

After receiving customer complaints, investigations confirmed the presence of a positive bias in D-Dimer measurements throughout the entire analytical range.

Feb 4, 2026Z-1491-2026—open, classified

The potential of out-of-range results and an underestimation of the free protein S level in normal patient plasmas. The defect only affects normal-range values.

Dec 15, 2025Z-1084-2026—open, classified

Potential for defect for Asserachrom HPIA lot 271288, which can affect every well in the impacted strip and produce negative results.

Sep 12, 2025Z-0205-2026—open, classified

A potential risk of underestimation of D-Dimer (D-Di) levels with the two listed lots.

Jul 21, 2025Z-2474-2025—open, classified

Potential for contamination of STA-LIQUID ANTI-Xa by Stago Fibrinogen reagents in UFH and LMWH applications.

Jul 21, 2025Z-2476-2025—open, classified

Potential for contamination of STA-LIQUID ANTI-Xa by Stago Fibrinogen reagents in UFH and LMWH applications.

Jul 21, 2025Z-2473-2025—open, classified

Potential for contamination of STA-LIQUID ANTI-Xa by Stago Fibrinogen reagents in UFH and LMWH applications.

Jul 21, 2025Z-2475-2025—open, classified

Potential for contamination of STA-LIQUID ANTI-Xa by Stago Fibrinogen reagents in UFH and LMWH applications.

May 21, 2025Z-1993-2025—open, classified

Potential for shorter clotting times in clotting tests which have a dilution, leading to possible overestimate of around 1%

Mar 22, 2023Z-1575-2023—open, classified

An internal investigation identified a bug in this firmware version, resulting in the following:Intermittent shortened coagulation times and an increased frequency of occurrence of a technical error reported by the analyzer (error 13).

Mar 22, 2023Z-1576-2023—open, classified

An internal investigation identified a bug in this firmware version, resulting in the following:Intermittent shortened coagulation times and an increased frequency of occurrence of a technical error reported by the analyzer (error 13).

Mar 22, 2023Z-1577-2023—open, classified

An internal investigation identified a bug in this firmware version, resulting in the following:Intermittent shortened coagulation times and an increased frequency of occurrence of a technical error reported by the analyzer (error 13).

Mar 4, 2020Z-1699-2020—terminated

A risk of sample-to-sample cross-contamination of Emicizumab for factor VIII assays on Stago instruments, clotting times will be shortened that may cause factor VIII levels reported to be falsely increased

Nov 18, 2019Z-0737-2020—terminated

A positive bias was confirmed to exists on the STA - Unicalibrator levels with STA - Deficient IX and STA - Deficient VIII when compared to the International Standard (IS) for factor VIII or IX. This bias is also observed on several External Quality Assessment (EQA) results.

Nov 18, 2019Z-0738-2020—terminated

A positive bias was confirmed to exists on the STA - Unicalibrator levels with STA - Deficient IX and STA - Deficient VIII when compared to the International Standard (IS) for factor VIII or IX. This bias is also observed on several External Quality Assessment (EQA) results.

Nov 14, 2018Z-0611-2019—terminated

There have been reports of shortened (T1-T2) results, where some instances of result recovery outside of the range of less than or equal to 15 seconds.

Nov 14, 2018Z-0610-2019—terminated

There have been reports of shortened (T1-T2) results, where some instances of result recovery outside of the range of less than or equal to 15 seconds.

Jul 24, 2018Z-2993-2018—terminated

QC values outside of the assigned ranges (prolonged Prothrombin time / decreased PT %)

Jul 24, 2018Z-2994-2018—terminated

QC values outside of the assigned ranges (prolonged Prothrombin time / decreased PT %)

Oct 25, 2017Z-1067-2018—terminated

Confirmed defect of homogeneity where some reagent vials will give prolonged Prothrombin Time (decreased PT%).

Oct 25, 2017Z-1066-2018—terminated

Confirmed defect of homogeneity where some reagent vials will give prolonged Prothrombin Time (decreased PT%).

Oct 25, 2017Z-1069-2018—terminated

Confirmed defect of homogeneity where some reagent vials will give prolonged Prothrombin Time (decreased PT%).

Oct 25, 2017Z-1068-2018—terminated

Confirmed defect of homogeneity where some reagent vials will give prolonged Prothrombin Time (decreased PT%).

Jul 18, 2014Z-2650-2014—terminated

Diagnostica Stago Inc. received some customer complaints regarding a misreading of Reagent 1 (substrate) barcode on STA analyzers.

Jan 28, 2013Z-0951-2013—terminated

Diagnostica Stago has confirmed that sometimes the delta OD measured can be changed leading to a lowered percentage result.

Jun 15, 2012Z-0252-2013—terminated

Following a single customer complaint that incorrect INR values were occasionally printed for PT tests, even though the primary units (seconds) were correct, the firm investigated and confirmed the potential for printing incorrect secondary units when using an external printer and the customer printout mode on the STA Satellite.

Aug 23, 2011Z-1044-2012—terminated

Factor VIII quality control results are being recovered below the assigned ranges for STA System Control N+P.

Oct 20, 2008Z-0502-2009—terminated

Internal investigation has determined the potential lack of homogeneity between product vials.

Oct 20, 2008Z-0501-2009—terminated

Internal investigation has determined the potential lack of homogeneity between product vials.

Jul 30, 2007Z-0039-2008—terminated

Incorrect results. Internal investigation determined the presence of a defective measurement head which can impact the results of clotting tests by either yielding no result or rendering an error message.

May 8, 2007Z-1072-2007—terminated

Specific lots of STA Liatest Free Protein S may result in low results in the assigned value ranges and sometimes outside the lower limit.

Mar 30, 2007Z-0979-2007—terminated

Based on the confirmed clotting times in the upper part of the assigned ranges of STA-Coag Control ABN control plasmas when used with STA-Neoplastine CI Plus, use of this lot may cause difficulty during the validation of the STA-Coag Control ABN.

Mar 13, 2007Z-0853-2007—terminated

A dose-hook effect is observed starting from VWF:AG levels of 300%, while the package insert indicates that no dose-hook effect has been observed with VWF:Ag levels up to 800%.

Jan 18, 2007Z-0812-2007—terminated

Result of complaints of field failures of the silicon bridge rectifier, resulting in smoke billowing out of the unit and burnt circuit boards, wires and connectors.

Jul 18, 2006Z-1441-06—terminated

Decrease in sensitivity ; This could result in a false negative result for patients with weak to moderate lupus anticoagulants.

Oct 26, 2005Z-0408-06—terminated

The mean levels (%) of normal and abnormal control plasmas (STA Liatest Control N and P) obtained with STA Liatest Free Protein S are found in the lower part of the range.

Jun 20, 2005Z-1422-05—terminated

Concerning the STA-R blood coagulation analyzer, there is a possible failure mode associated with patient samples receiving prolonged exposure time to reagents during the cuvette roll change process.

Apr 13, 2005Z-1419-05—terminated

Variable clotting times observed with the PTT-LA, Lupus Anticoagulant-Sensitive APTT Reagent.

Mar 5, 2003Z-0899-03—terminated

With maintenance of the STA line, the cap-piercing feature may involve potential risk of needle puncture injury.

Dec 20, 2002Z-1081-04—terminated

Incorrect assay ranges on the assay value insert for Heparin Control 5.

Dec 4, 2002Z-1080-04—terminated

The FDP Plasma latex reagent (Reagent Vial 1) is more sensitive which may result in a weak agglutination at low concentration of FDPs.

FDA Establishments (1)

Establishments registered with the FDA under this company group, matched by name.

  • Diagnostica Stago, Inc. PARSIPPANY, NJ · US FEI 2245451